IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v108y2012i2p178-193.html
   My bibliography  Save this article

The politics of health technology assessment in Poland

Author

Listed:
  • Ozieranski, Piotr
  • McKee, Martin
  • King, Lawrence

Abstract

First, to identify risks associated with the scientific evaluation of drugs considered for state reimbursement in Poland through exploring strategies of influence employed by multinational drug companies in relation to the Agency for Health Technology Assessment (AHTAPol). Second, to ascertain whether the outcomes of drug evaluation meet the interests of the public payer in reimbursing cost-effective drugs supported by robust pharmacoeconomic evidence.

Suggested Citation

  • Ozieranski, Piotr & McKee, Martin & King, Lawrence, 2012. "The politics of health technology assessment in Poland," Health Policy, Elsevier, vol. 108(2), pages 178-193.
    • Handle: RePEc:eee:hepoli:v:108:y:2012:i:2:p:178-193
    DOI: 10.1016/j.healthpol.2012.10.001
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851012002825
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2012.10.001?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Christopher Hood, 2007. "What happens when transparency meets blame-avoidance?," Public Management Review, Taylor & Francis Journals, vol. 9(2), pages 191-210, June.
    2. Abelson, Julia & Giacomini, Mita & Lehoux, Pascale & Gauvin, Francois-Pierre, 2007. "Bringing `the public' into health technology assessment and coverage policy decisions: From principles to practice," Health Policy, Elsevier, vol. 82(1), pages 37-50, June.
    3. Janine R. Wedel, 2003. "Clans, cliques and captured states: rethinking 'transition' in Central and Eastern Europe and the former Soviet Union," Journal of International Development, John Wiley & Sons, Ltd., vol. 15(4), pages 427-440.
    4. Hood, Christopher & Rothstein, Henry & Baldwin, Robert, 2004. "The Government of Risk: Understanding Risk Regulation Regimes," OUP Catalogue, Oxford University Press, number 9780199270019.
    5. Gordon Boyce & Cindy Davids, 2009. "Conflict of Interest in Policing and the Public Sector," Public Management Review, Taylor & Francis Journals, vol. 11(5), pages 601-640, September.
    6. Kolasa, Katarzyna & Schubert, Sebastian & Manca, Andrea & Hermanowski, Tadeusz, 2011. "A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland," Health Policy, Elsevier, vol. 102(2), pages 145-151.
    7. Abraham, John, 2010. "On the prohibition of conflicts of interest in pharmaceutical regulation: Precautionary limits and permissive challenges. A commentary on Sismondo (66:9, 2008, 1909-14) and O'Donovan and Lexchin," Social Science & Medicine, Elsevier, vol. 70(5), pages 648-651, March.
    8. Lexchin, Joel & O'Donovan, Orla, 2010. "Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies," Social Science & Medicine, Elsevier, vol. 70(5), pages 643-647, March.
    9. Ozierański, Piotr & McKee, Martin & King, Lawrence, 2012. "Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?," Health Economics, Policy and Law, Cambridge University Press, vol. 7(2), pages 175-195, April.
    10. Sismondo, Sergio, 2008. "How pharmaceutical industry funding affects trial outcomes: Causal structures and responses," Social Science & Medicine, Elsevier, vol. 66(9), pages 1909-1914, May.
    Full references (including those not matched with items on IDEAS)

    Citations

    RePEc Biblio mentions

    As found on the RePEc Biblio, the curated bibliography for Economics:
    1. > Economic Development Technological Change, and Growth > Technological Change: Choices and Consequences > Technology Assessment > Health Technology Assessment

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Stuart Hogarth & Paul Martin, 2021. "The ratio of vision to data: Promoting emergent science and technologies through promissory regulation, the case of the FDA and personalised medicine," Regulation & Governance, John Wiley & Sons, vol. 15(3), pages 969-986, July.
    2. Wranik, Wiesława Dominika & Zielińska, Dorota Anna & Gambold, Liesl & Sevgur, Serperi, 2019. "Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland," Health Policy, Elsevier, vol. 123(2), pages 191-202.
    3. L. Gulácsi & M. Péntek, 2014. "HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(7), pages 675-680, September.
    4. Aris Angelis & Ansgar Lange & Panos Kanavos, 2018. "Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 123-152, January.
    5. Csanádi, Marcell & Ozierański, Piotr & Löblová, Olga & King, Lawrence & Kaló, Zoltán & Botz, Lajos, 2019. "Shedding light on the HTA consultancy market: Insights from Poland," Health Policy, Elsevier, vol. 123(12), pages 1237-1243.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Padamsee, Tasleem Juana, 2011. "The pharmaceutical corporation and the 'good work' of managing women's bodies," Social Science & Medicine, Elsevier, vol. 72(8), pages 1342-1350, April.
    2. Unruh, Lynn & Rice, Thomas & Rosenau, Pauline Vaillancourt & Barnes, Andrew J., 2016. "The 2013 cholesterol guideline controversy: Would better evidence prevent pharmaceuticalization?," Health Policy, Elsevier, vol. 120(7), pages 797-808.
    3. Csanádi, Marcell & Ozierański, Piotr & Löblová, Olga & King, Lawrence & Kaló, Zoltán & Botz, Lajos, 2019. "Shedding light on the HTA consultancy market: Insights from Poland," Health Policy, Elsevier, vol. 123(12), pages 1237-1243.
    4. Jabbar, Amina M. & Abelson, Julia, 2011. "Development of a framework for effective community engagement in Ontario, Canada," Health Policy, Elsevier, vol. 101(1), pages 59-69, June.
    5. Julien Etienne, 2015. "Different ways of blowing the whistle: Explaining variations in decentralized enforcement in the UK and France," Regulation & Governance, John Wiley & Sons, vol. 9(4), pages 309-324, December.
    6. Aven, Terje & Renn, Ortwin, 2018. "Improving government policy on risk: Eight key principles," Reliability Engineering and System Safety, Elsevier, vol. 176(C), pages 230-241.
    7. S Scott Graham & Zoltan P Majdik & Dave Clark & Molly M Kessler & Tristin Brynn Hooker, 2020. "Relationships among commercial practices and author conflicts of interest in biomedical publishing," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-11, July.
    8. Gérard Mondello, 2020. "Building Belief Systems and Medical Ethics: The Covid-19 Controversies," GREDEG Working Papers 2020-35, Groupe de REcherche en Droit, Economie, Gestion (GREDEG CNRS), Université Côte d'Azur, France.
    9. Jeroen van der Heijden & Jitske de Jong, 2009. "Towards a Better Understanding of Building Regulation," Environment and Planning B, , vol. 36(6), pages 1038-1052, December.
    10. Livia Johannesson & Noomi Weinryb, 2021. "How to blame and make a difference: perceived responsibility and policy consequences in two Swedish pro-migrant campaigns," Policy Sciences, Springer;Society of Policy Sciences, vol. 54(1), pages 41-62, March.
    11. Anaïs Valiquette L’Heureux, 2022. "The Case Study of Los Angeles City & County Fraud, Embezzlement and Corruption Safeguards during times of pandemic," Public Organization Review, Springer, vol. 22(3), pages 593-610, September.
    12. Peter J. May, 2007. "Regulatory regimes and accountability," Regulation & Governance, John Wiley & Sons, vol. 1(1), pages 8-26, March.
    13. Julia Black & Robert Baldwin, 2012. "When risk‐based regulation aims low: Approaches and challenges," Regulation & Governance, John Wiley & Sons, vol. 6(1), pages 2-22, March.
    14. Mathias Ericson, 2018. "“Sweden Has Been Naïve”: Nationalism, Protectionism and Securitisation in Response to the Refugee Crisis of 2015," Social Inclusion, Cogitatio Press, vol. 6(4), pages 95-102.
    15. Demortain, David, 2008. "Institutional polymorphism: the designing of the European Food Safety Authority with regard to the European Medicines Agency," LSE Research Online Documents on Economics 36534, London School of Economics and Political Science, LSE Library.
    16. L. Gulácsi & E. Orlewska & M. Péntek, 2012. "Health economics and health technology assessment in Central and Eastern Europe: a dose of reality," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 525-531, October.
    17. Jeff Everett & Constance Friesen & Dean Neu & Abu Shiraz Rahaman, 2018. "We Have Never Been Secular: Religious Identities, Duties, and Ethics in Audit Practice," Journal of Business Ethics, Springer, vol. 153(4), pages 1121-1142, December.
    18. Govender, Urishanie & van Eck, Gary & Genc, Bekir, 2022. "An integrated 4Cs safety framework for the diamond industry of Southern Africa," Resources Policy, Elsevier, vol. 77(C).
    19. Li, Kathy K. & Abelson, Julia & Giacomini, Mita & Contandriopoulos, Damien, 2015. "Conceptualizing the use of public involvement in health policy decision-making," Social Science & Medicine, Elsevier, vol. 138(C), pages 14-21.
    20. Dumitriu, Ramona & Stefanescu, Răzvan, 2016. "Strategic decisions on industrialization: case of Galati Steel Works," MPRA Paper 89007, University Library of Munich, Germany, revised 2016.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:108:y:2012:i:2:p:178-193. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.